Breast Cancer
Breast cancer, the second most common cancer in women after skin cancer, develops from breast tissue and may present with symptoms like a lump, changes in breast shape, skin dimpling, or nipple discharge. Early detection through regular exams is crucial for more effective treatment.
Health Outcomes
- Accelerated Recovery of Chemotherapy-Induced Myelosuppression
- Activated Wnt/Beta-Catenin Signaling
- Activated p53/BAX-Mediated DNA Damage Response
- Additive Antitumorigenic Effect
- Altered Breast Chemical Composition
- Cancer Treatment Support
- Changed Leukocyte Telomere Length
- Delayed Tumor Onset
- Downregulated Hippo Pathway Kinase Activity
- Enhanced Anticancer Capacity
- Enhanced Antitumor Immune Response
- Enhanced Antitumor Immunity
- Enhanced CD8+ T Cell Infiltration
- Enhanced Caspase-3 Activity
- Enhanced Cell Adhesion
- Enhanced Cell Adhesion Capacity
- Enhanced Cell Viability
- Enhanced Cytolytic Response of CD8+ T Cells
- Enhanced DNA Repair
- Enhanced Glycolysis Pathway Activation
- Enhanced Natural Killer Cell Activity
- Enhanced Natural Killer Cell Tumor Killing Activity
- Enhanced Natural Killer Cell Tumoricidal Activity
- Enhanced Pro-Apoptotic MAPK Signaling
- Enhanced Tumor-Targeted Drug Delivery
- Estrogen Receptor-Mediated Effects
- Extended Survival Periods
- Genome Sequencing / Genome Characterization
- Identification of FDA Approved Drug Target Regulators
- Improved Antitumor Response
- Improved Breast Cancer Therapy Response
- Improved Cancer-Related Health Outcome
- Improved Cell Viability
- Improved Chemotherapy Efficacy
- Improved Clinical Success
- Improved Effectiveness in Cancer Treatment
- Improved Efficacy Rate
- Improved FACT-B Score
- Improved Histopathological Indicators
- Improved Karnofsky Performance Status
- Improved NK-Cell Cytotoxicity
- Improved Natural Killer Cell Activation
- Improved Natural Killer Cell Activity
- Improved Natural Killer Cell Tumoricidal Activity
- Improved Objective Response Rate
- Improved Oncolytic Virotherapy Efficacy
- Improved Overall Survival
- Improved Pathological Response
- Improved Post-Challenge Survival
- Improved Prognosis Post-Recovery
- Improved Progression-free Survival
- Improved Remission
- Improved Resistance to Sodium Selenite
- Improved Response Rate
- Improved Response to Treatment
- Improved Survival
- Improved Survival Capacity
- Improved Survival During Cryopreservation
- Improved Survival Rate
- Improved Therapeutic Potential
- Improved Treatment Efficacy
- Improved Treatment Response Rate
- Improved Tumor Response
- Inactivated Other Receptor Tyrosine Kinase Activity
- Increased Anti-Tumor Activity
- Increased Antiangiogenic Activity
- Increased Anticancer Activity
- Increased Anticancer Treatment Adherence
- Increased Autophagy
- Increased Bifidobacterium spp. DNA in Lymph Nodes
- Increased Catalase Expression
- Increased Cell Death
- Increased Cell Division
- Increased Chromosomal Instability
- Increased Cure Rate after Conventional Treatment
- Increased EGF Level
- Increased Estradiol Level
- Increased Estrogen Level
- Increased Glycolysis Pathway Activity
- Increased Insulin-like Growth Factor-1 Level
- Increased Intratumoral Accumulation
- Increased Intratumoral CD8+ T-cell Expansion
- Increased Lesion Detection Rate
- Increased Mitogenic Activity
- Increased NK Cell Activity
- Increased PUFA Levels in Breast Milk
- Increased Peak Estradiol Concentration
- Increased Peroxidase Activity
- Increased Plasma Daidzein Levels
- Increased Polyamine Levels
- Increased Polyamine Production
- Increased Progesterone Level
- Increased Proportion of Responders
- Increased Reduced Glutathione Level
- Increased Relative Survival Percentage
- Increased Survival Rate
- Increased Survival Time
- Increased Survival in Tumor-Bearing Mice
- Increased Telomere Length
- Increased Tissue Invasion
- Increased VEGF Level
- Increased mTORC1 Activation
- Influenced Cell Differentiation
- Inhibited EGF Receptor Signaling
- Inhibited Epithelial-Mesenchymal Transition
- Inhibited PI3K/AKT Pathway
- Maintained Natural Killer Cell Activity
- Managed Vasomotor Symptoms
- No Improvement in Objective Cancer Treatment Response
- No Mutagenicity
- No Serious Treatment-Related Adverse Events
- No Significant Change in Breast Composition
- No Significant Change in Lean Body Mass
- Overall Treatment Success
- Reduced Apoptosis Due to Carcinogens
- Reduced CEA Levels
- Reduced COX-2 Levels
- Reduced Cancer Activity
- Reduced Cancer Progression
- Reduced Cancer Risk
- Reduced Cancer-Related Inflammation
- Reduced Cancer-Specific Mortality
- Reduced Carcinogenesis
- Reduced Caspase-3 Activity
- Reduced Cause-Specific Mortality
- Reduced Cell Adhesion
- Reduced Cell Apoptosis
- Reduced Chemotherapy Side Effects
- Reduced DNA Damage
- Reduced Epithelial Cell Apoptosis
- Reduced Epithelial-Mesenchymal Transition
- Reduced Expression of STAT3-Dependent Tumor-Associated Genes
- Reduced Fas Level
- Reduced Genotoxicity
- Reduced IkappaB Alpha Degradation
- Reduced Lymphocytic Genome Damage
- Reduced Mammary Gland Ferroptosis
- Reduced Plasma Equol Concentration
- Reduced Postoperative Fatigue
- Reduced Pulmonary Metastasis
- Reduced Radiation-Induced Dermatitis Severity
- Reduced Recurrence Risk
- Reduced Risk of Cancer
- Reduced Survival Rate
- Reduced Tumor Downstaging
- Reduced Tumor Formation
- Reduced Tumor Grade
- Reduced Tumor Growth
- Reduced Tumor Growth Rate
- Reduced Tumor Incidence
- Reduced Tumor Multiplicity
- Reduced Tumor Risk
- Reduced Tumor Stage
- Reduced Tumor Volume
- Regulated miR-130a-5p Levels
- Shifted Tumor-Associated Macrophages Toward Pro-Inflammatory M1 Polarization
- Stabilized Disease Progression
- Supportive Effect in Breast Cancer Management
- Suppressed Tumor Growth
- Suppressed Wnt/β-catenin Signaling
- Targeted Tumor Reduction
- Upregulated Macrophage Inhibitory Factor